Momenta Presents Three Glatopa (glatiramer acetate injection) Posters at ECTRIMS 2015 Meeting
October 01 2015 - 8:00AM
Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology
company specializing in the characterization and engineering of
complex drugs, today announced the upcoming presentation of three
posters summarizing the key data developed to demonstrate
equivalence between GlatopaTM and daily COPAXONE® 20 mg (glatiramer
acetate injection). The posters will be presented at the 31st
Congress of the European Committee for Treatment and Research in
Multiple Sclerosis (ECTRIMS) in Barcelona, Spain, and will
summarize the overall approach used to evaluate equivalence of the
two glatiramer acetate products as well as showcase numerous
examples of biological and other key assays.
Poster Presentation Details
Title: “Comparative gene expression profiling
between Glatopa™ and Copaxone® 20 mg”Poster Number: P641Session
Title: Poster Session ISession Date: Thursday, 8 October
2015Presenting Time: 15:45 – 17:00 hr
Title: “Use of multiple, high resolution,
orthogonal assays for demonstration of biological and immunological
equivalence of Glatopa™ and Copaxone® 20 mg”Poster Number:
P647Session Title: Poster Session ISession Date: Thursday, 8
October 2015Presenting Time: 15:45 – 17:00 hr
Title: “Demonstration of equivalence between
Glatopa™ and Copaxone® 20 mg”Poster Number: P1143Session Title:
Poster Session IISession Date: Friday, 9 October 2015Presenting
Time: 15:30 – 17:00 hr
About GlatopaTM
Once daily Glatopa (glatiramer acetate
injection), developed in collaboration with Sandoz, is the first
FDA-approved generic version of daily COPAXONE® 20 mg for patients
with relapsing forms of multiple sclerosis. Produced entirely in
the United States, once daily Glatopa has been determined by the
FDA to be therapeutically equivalent to daily COPAXONE 20 mg, and
is an “AP” rated, fully-substitutable product. As a therapeutically
equivalent generic product, once daily Glatopa contains the same
active ingredients, route of administration, strength, and dosage
form, and can be substituted with the full expectation that Glatopa
will produce the same clinical effect and safety profile as daily
COPAXONE 20 mg. Daily COPAXONE 20 mg is one of the leading products
marketed to treat multiple sclerosis, and is frequently prescribed
as a first-line therapy in newly diagnosed patients.
About Momenta
Momenta Pharmaceuticals is a biotechnology company specializing
in the detailed structural and functional analysis of complex drugs
and is headquartered in Cambridge, MA. Momenta is applying
its technology to the development of generic versions of complex
drugs, biosimilar and potentially interchangeable biologics, and to
the discovery and development of novel therapeutics for oncology
and autoimmune indications.
To receive additional information about Momenta,
please visit the website at www.momentapharma.com, which does not
form a part of this press release. The company’s logo, trademarks,
and service marks are the property of Momenta Pharmaceuticals, Inc.
All other trade names, trademarks, or service marks are property of
their respective owners.
COPAXONE is a registered trademark of Teva Pharmaceuticals.
Glatopa is a trademark of Novartis AG.
Investor Relations:
Sarah Carmody
Momenta Pharmaceuticals
1-617-395-5189
IR@momentapharma.com
Media Relations:
Karen Sharma
MacDougall Biomedical Communications
1-781-235-3060
Momenta@macbiocom.com
Momenta Pharmaceuticals (NASDAQ:MNTA)
Historical Stock Chart
From Apr 2024 to May 2024
Momenta Pharmaceuticals (NASDAQ:MNTA)
Historical Stock Chart
From May 2023 to May 2024